Literature DB >> 12938215

B cell activation leads to shedding of complement receptor type II (CR2/CD21).

Madhan Masilamani1, Daniela Kassahn, Stefan Mikkat, Michael O Glocker, Harald Illges.   

Abstract

Complement receptor type II (CR2/CD21) is the major receptor for C3d fragments on immune complexes. CD21 also serves as the receptor for Epstein-Barr virus in humans. On mature B cells, CD21 reduces the threshold of BCR signaling together with CD81, Leu13 and CD19, but it also occurs on other cells of the immune system where it performs unknown functions. A soluble form of CD21 (sCD21) is shed from the cell surface and is found in human blood plasma. An as-yet-unknown protease is thought to be responsible for this shedding. Altered levels of sCD21 occur in plasma in certain clinical conditions. We show here by mass spectrometry that sCD21 in human plasma of healthy donors is predominantly a short form of CD21 without the exon-11-encoded sequences. Whereas the N terminus of sCD21 was found unmodified, the C terminus is truncated, implying that only the extracellular portion of CD21 is shed. Peripheral blood B cells, but not T cells, contribute to the plasma CD21-pool. CD21 shedding is induced by stimulation with PMA plus Ca(2+) ionophore, or by stimulation of the BCR with anti-IgM+anti-CD40.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12938215     DOI: 10.1002/eji.200323843

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  21 in total

Review 1.  PD-1 immunobiology in systemic lupus erythematosus.

Authors:  Colleen S Curran; Sarthak Gupta; Ignacio Sanz; Elad Sharon
Journal:  J Autoimmun       Date:  2018-11-03       Impact factor: 7.094

2.  Similar CD19 dysregulation in two autoantibody-associated autoimmune diseases suggests a shared mechanism of B-cell tolerance loss.

Authors:  Donna A Culton; Matilda W Nicholas; Donna O Bunch; Quan Li Zhen; Thomas B Kepler; Mary Anne Dooley; Chandra Mohan; Patrick H Nachman; Stephen H Clarke
Journal:  J Clin Immunol       Date:  2006-12-29       Impact factor: 8.317

3.  Soluble CD21 in sera and synovial fluid of arthritic patients.

Authors:  Thomas Grottenthaler; Johannes von Kempis; Sigune Goldacker; Harald Illges
Journal:  Rheumatol Int       Date:  2005-03-16       Impact factor: 2.631

4.  A new mouse anti-mouse complement receptor type 2 and 1 (CR2/CR1) monoclonal antibody as a tool to study receptor involvement in chronic models of immune responses and disease.

Authors:  Liudmila Kulik; Finnegan B Hewitt; Van C Willis; Rosa Rodriguez; Stephen Tomlinson; V Michael Holers
Journal:  Mol Immunol       Date:  2015-02       Impact factor: 4.407

5.  Enhanced CD21 expression and shedding in chronic lymphatic leukemia: a possible pathomechanism in disease progression.

Authors:  Hui Zhi Low; Dorothee Hilbrans; Ingo G H Schmidt-Wolf; Harald Illges
Journal:  Int J Hematol       Date:  2012-08-17       Impact factor: 2.490

6.  Targeting the Immune Complex-Bound Complement C3d Ligand as a Novel Therapy for Lupus.

Authors:  Liudmila Kulik; Jennifer Laskowski; Brandon Renner; Rachel Woolaver; Lian Zhang; Taras Lyubchenko; Zhiying You; Joshua M Thurman; V Michael Holers
Journal:  J Immunol       Date:  2019-11-15       Impact factor: 5.422

7.  Pathogenic natural antibodies recognizing annexin IV are required to develop intestinal ischemia-reperfusion injury.

Authors:  Liudmila Kulik; Sherry D Fleming; Chantal Moratz; Jason W Reuter; Aleksey Novikov; Kuan Chen; Kathy A Andrews; Adam Markaryan; Richard J Quigg; Gregg J Silverman; George C Tsokos; V Michael Holers
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

Review 8.  The genetics of hypogammaglobulinemia.

Authors:  Bodo Grimbacher; Alejandro A Schäffer; Hans-Hartmut Peter
Journal:  Curr Allergy Asthma Rep       Date:  2004-09       Impact factor: 4.806

9.  Antiphospholipid syndrome patients display reduced titers of soluble CD21 in their sera irrespective of circulating anti-beta2-glycoprotein-I autoantibodies.

Authors:  Anjana Singh; Miri Blank; Yehuda Shoenfeld; Harald Illges
Journal:  Rheumatol Int       Date:  2008-01-03       Impact factor: 2.631

10.  Systemic reduction of soluble complement receptor II/CD21 during pregnancy to levels reminiscent of autoimmune disease.

Authors:  Madhan Masilamani; Narendiran Rajasekaran; Anjana Singh; Hui-Zhi Low; Kerstin Albus; Swantje Anders; Frank Behne; Peter Eiermann; Katharina König; Clarissa Mindnich; Teodora Ribarska; Harald Illges
Journal:  Rheumatol Int       Date:  2008-05-24       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.